Stock Comparison

JNJ vs RXRX

Johnson & Johnson vs Recursion Pharmaceuticals Inc

The Verdict

RXRX takes this one.

JNJ

Johnson & Johnson

1.0

out of 10

Distressed

Winner

RXRX

Recursion Pharmaceuticals Inc

6.3

out of 10

Solid Pick

Head-to-Head

$557.1B

Market Cap

$1.8B

26.5

P/E Ratio

-2.3

21.8%

Profit Margin

-842.9%

26.3%

Return on Equity

-54.3%

0.6

Debt-to-Equity

0.0

Conservative

Overall Risk

Aggressive

1.0

DVR Score

6.3

The Deep Dive

JNJ1.0/10

Johnson & Johnson (JNJ) continues to demonstrate robust financial performance, with Q1 2026 results exceeding consensus on both revenue and adjusted EPS, reflecting nearly 10% YoY revenue growth. Its diversified healthcare portfolio provides significant market leadership and a wide economic moat, indicating stability and consistent profitability. However, its massive market capitalization of $555....

Full JNJ Analysis

RXRX6.3/10

Recursion Pharmaceuticals (RXRX) continues to present a compelling long-term vision leveraging its AI/ML Biofoundry to disrupt drug discovery, backed by a strong cash position ($665.2M). The analyst targets (median $9.0) significantly above the current price ($3.44) indicate underlying institutional belief in its future. However, the Q1 2026 earnings revealed a significant challenge: collaboration...

Full RXRX Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.